Evidence map›Paper›PMID 37376102›Full record

ArticlePharmaceutics2023

Mesenchymal Stem Cell Membrane-Coated TPCS

Greta Avancini, Luca Menilli, Adele Visentin, Celeste Milani, Francesca Mastrotto, Francesca Moret

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Greta AvanciniDepartment of Biology, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0001-8792-342X
Luca MenilliDepartment of Biology, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0003-2774-6411
Adele VisentinDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy.
Celeste MilaniDepartment of Biology, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy.
Francesca MastrottoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy.ORCID 0000-0002-2499-5490
Francesca MoretDepartment of Biology, University of Padova, Via Ugo Bassi 58/B, 35131 Padova, Italy.ORCID 0000-0002-1534-3714

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite substantial improvements in breast cancer (BC) treatment there is still an urgent need to find alternative treatment options to improve the outcomes for patients with advanced-stage disease. Photodynamic therapy (PDT) is gaining a lot of attention as a BC therapeutic option because of its selectivity and low off-target effects. However, the hydrophobicity of photosensitizers (PSs) impairs their solubility and limits the circulation in the bloodstream, thus representing a major challenge. The use of polymeric nanoparticles (NPs) to encapsulate the PS may represent a valuable strategy to overcome these issues. Herein, we developed a novel biomimetic PDT nanoplatform (NPs) based on a polymeric core of poly(lactic-co-glycolic)acid (PLGA) loaded with the PS meso-tetraphenylchlorin disulfonate (TPCS

Indexed as

biomimetic nanoparticlesbreast cancerphotodynamic therapy

Identifiers

PMID37376102
PMCPMC10302938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.